Quote this publication Share Print

JAKAVI (ruxolitinib), protein kinase inhibitor

ONCOLOGY - New indication
Opinions on drugs - Posted on Feb 29 2016

Reason for request

Extension of inclusion

Minor improvement in second-line treatment of polycythemia vera.

 

  • JAKAVI now has Marketing Authorisation in the treatment of adults with polycythemia vera who are resistant or intolerant to hydroxyurea.

  • It provides a minor improvement in the short term, due to better safety and an improvement of symptoms. There are no long-term safety data.

 

 


Clinical Benefit

Substantial

-


Clinical Added Value

minor

-


Therapeutic use

-

Contact Us

Évaluation des médicaments